Evercore ISI Group has initiated coverage on Transmedics Group Inc (TMDX) with an Outperform rating as of September 15, 2025. This marks the firm's first assessment of the company, reflecting its analysis of Transmedics' business model and growth potential.
Transmedics Group operates as a commercial-stage medical technology company, headquartered in Andover, Massachusetts. The firm specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) replicates near-physiologic conditions for donor organs outside the human body, while its National OCS Program (NOP) offers outsourced organ procurement and transplant logistics services across the United States.
As of November 20, 2025, Transmedics has a market capitalization of $4.2 billion, a P/E ratio of 46.19, and an EPS of 2.29. Upcoming earnings are scheduled for July 28, 2026, with an estimated EPS of $0.81 and revenue of $189.2 million.
The announcement highlights the growing interest in Transmedics, which has received a consensus rating of Buy from analysts, with 7 Strong Buy, 8 Buy, and 4 Hold ratings noted as of November 1, 2025. Recent earnings performance has shown significant surprises, with Q3 2025 EPS reported at $0.66, exceeding estimates by 84.4%.